Metformin and longevity (METAL): a window of opportunity study investigating the biological effects of metformin in localised prostate cancer

BACKGROUND: Metformin is a biguanide oral hypoglycaemic agent commonly used for the treatment of type 2 diabetes mellitus. In addition to its anti-diabetic effect, metformin has also been associated with a reduced risk of cancer incidence of a number of solid tumours, including prostate cancer (PCa)...

Descripción completa

Detalles Bibliográficos
Autores principales: Crawley, Danielle, Chandra, Ashish, Loda, Massimo, Gillett, Cheryl, Cathcart, Paul, Challacombe, Ben, Cook, Gary, Cahill, Declan, Santa Olalla, Aida, Cahill, Fidelma, George, Gincy, Rudman, Sarah, Van Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520293/
https://www.ncbi.nlm.nih.gov/pubmed/28732480
http://dx.doi.org/10.1186/s12885-017-3458-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520293/
https://www.ncbi.nlm.nih.gov/pubmed/28732480
http://dx.doi.org/10.1186/s12885-017-3458-3

Ejemplares similares